Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00141323
Status:
COMPLETED
Last Update Posted:
2011-08-15
First Post:
2005-08-30
Brief Title:
Postmenopausal Evaluation and Risk-reduction With Lasofoxifene PEARL
Sponsor:
Ligand Pharmaceuticals
Organization:
Ligand Pharmaceuticals
Study Overview
Official Title:
PEARL Postmenopausal Evaluation And Risk-Reduction With Lasofoxifene
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PEARL
Brief Summary:
The purpose of the study is to determine the safety and effectiveness of 2 doses of the investigational drug lasofoxifene compared to placebo an inactive substance in reducing new spinal fractures in women with osteoporosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None